BioAtla Shares Are Trading Higher After the Company Reported Better-than-expected Q1 GAAP EPS Results.

BioAtla Shares Are Trading Higher After the Company Reported Better-than-expected Q1 GAAP EPS Results.

BenzingaMay 15 12:37 ET

Express News | HC Wainwright & Co. Reiterates Buy on BioAtla, Maintains $7 Price Target

BenzingaMay 15 11:19 ET

BioAtla Analyst Ratings

Date Upside/Downside Analyst Firm Price Target Change Rating Change Previous / Current Rating 05/15/2024 137.29% HC Wainwright & Co. → $7 Reiterates Buy → Buy 03/28/2024 306.78% JMP Securities → $12 R

BenzingaMay 15 11:18 ET

Exchange-Traded Funds Higher, Equity Futures Mixed Pre-Bell Wednesday Ahead of Key Inflation, Retail Data

The broad market exchange-traded fund SPDR S&P 500 ETF Trust (SPY) was up 0.1% and the actively traded Invesco QQQ Trust (QQQ) edged up 0.04% in Wednesday's premarket activity, ahead of key inflation

MT NewswiresMay 15 08:17 ET

Buy Rating Affirmed for BioAtla on Strong Clinical Data and Strategic Pipeline Progress

TipRanksMay 15 06:29 ET

Earnings Call Summary | BioAtla(BCAB.US) Q1 2024 Earnings Conference

The following is a summary of the BioAtla, Inc. (BCAB) Q1 2024 Earnings Call Transcript:Financial Performance:BioAtla reported R&D expenses of $18.9 million for Q1 2024, down from $21.7 million in Q1

moomoo AIMay 15 06:28 ET · Conference Call